Predictive biomarkers in colorectal cancer: Usage, validation, and design in clinical trials

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 3, 2012, Pages 356-362

  Shi, Qian ^a   Mandrekar, Sumithra J ^a   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

Author keywords

clinical trial design; clinical utility; predictive biomarker; validation

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; IMATINIB; K RAS PROTEIN; PANITUMUMAB; PEMETREXED; TRASTUZUMAB; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DISEASE COURSE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VALIDATION STUDY;

CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DECISION MAKING; HUMANS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 84857144592     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.640836     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Kinzler KW, Vogelstein B. Colorectal tumors. In Voelstein B, Kinzler KW, editors. The genetic basis of human cancer. 2nd ed. New York: NY, McGraw-Hill; 2002. pp 583-612.
3. Libutti SK, Saltz LB, Tepper JE. Colon Cancer. In DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's Cancer: Principles and practice of oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. pp 1232-84.
4. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl JMed 2009; 361:2449-60.
5. Gryfe R. Overview of colorectal cancer genetics. Surg Oncol Clin N Am 2009;18:573-83.
6. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7. (Pubitemid 46211382)
7. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 2005;5:317-25. (Pubitemid 41425609)
8. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009;15:1898-905.
9. BuyseM, SargentDJ, Grothey A,Matheson A, de Gramont A. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 2010;7:309-17.
10. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
11. Clark GM. Prognostic and Predictive Factors for. Breast Cancer Breast Cancer 1995;2:79-89.
12. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 1998;52:261-88. (Pubitemid 29056100)
13. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002;29:222-30. (Pubitemid 34620439)
14. Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. Clin Trials 2010;7: 567-73.
15. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
16. Freeman D, Juan T, Meropol NJ, et al. Association of KRAS gene mutations and clinical outcome in patients with metastatic colorectal cancer receiving panitumumab monotherapy. 14th European Cancer Conference, Barcelona, Spain, 2007.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
18. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008;26 (May 20 suppl; abstr 2).
19. Bokemeyer G, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, et al. KRAS status and efficacy of first-line treatment of patients with or without cetuximab: the OPUS experience. J Clin Oncol 2008;26 (May 20 suppl; abstr 4000).
20. Simon R. Validation of pharmacogenomic biomarker classifiers for treatment selection. Cancer Biomark 2006;2: 89-96.
21. Simon R. Development and Validation of Biomarker Classifiers for Treatment Selection. J Stat Plan Inference 2008;138: 308-20.
22. Paik S. Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Biotechnol Annu Rev 2003;9:259-67. (Pubitemid 41085858)
23. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
24. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004;10:6759-63. (Pubitemid 39383023)
25. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med 2005;24:329-39. (Pubitemid 40227650)
26. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
27. Mandrekar SJ, Sargent DJ. Genomic advances and their impact on clinical trial design. Genome Med 2009;1:69.
28. Pemetrexed or Erlotinib as Second-Line Therapy in Treating Patients With Advanced Non-Small Cell Lung Cancer, 2009. http://www.clinicaltrials.gov/ct2/ show/NCT00738881? term=NCT00738881&rank=1.
29. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8. (Pubitemid 41611633)
30. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010; 102:152-60.
31. Potti A, Nevins JR. Utilization of genomic signatures to direct use of primary chemotherapy. Curr Opin Genet Dev 2008; 18:62-7. (Pubitemid 351694449)
32. Hoering A, Leblanc M, Crowley JJ. Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res 2008;14:4358-67.
33. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007;6:227-44. (Pubitemid 47455262)
34. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007;99: 1036-43. (Pubitemid 47232604)
35. Mandrekar SJ, Sargent DJ. Clinical Validation of Biomarkers in Cancer. In: Molecular Diagnostics - The Key Driver in Personalized Cancer Medicine 2009.
36. Freidlin B, Jiang W, Simon R. The Cross-Validated Adaptive Sigature Design. Clin Cancer Res 2010;16:691-8.
37. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
38. Paik S, Kim C, Jeong J, Geyer CE, Romond EH, Mejia- Mejia O, et al. Benefit from adjuvant trastuzumab may not be confined to patient with IHC 3+ and/or FISH-positive tumors: central testing results from NSABP B-31. J Clin Oncol 2007;25:511.
39. Perez EA, Romond EH, Suman VJ, Jeong J, Davidson NE, Geyer CE, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25:512.
40. Mandrekar SJ, Sargent DJ. Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All. J Biopharm Stat 2009;19:317-25.
41. Young KY, Laird A, Zhou XH. The efficiency of clinical trial designs for predictive biomarker validation. Clin Trials 2010; 7:557-66.
42. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer. N Engl J Med 2010;363: 1693-703.
43. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Iafrate AJ, Shapiro G, et al. Impact of Crizotinib on Survival in Patients with Advanced, ALK-positive NSCLC Compared with Historical Controls. J Clin Oncol 2011;29((Suppl):abstract 7507.
44. Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 2007;4:147-55.
45. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-8. (Pubitemid 351264384)
46. Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008;26: 729-35. (Pubitemid 351264385)